Company Update (NASDAQ:IMMU): Here’s Why Immunomedics, Inc. Shares Are Falling 27%


ImmunoCellular Therapeutics Logo. (PRNewsFoto/ImmunoCellular Therapeutics)

Immunomedics, Inc. (NASDAQ:IMMU) announced that it has priced an underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock with anticipated gross proceeds of $30 million. Each share of common stock and accompanying warrant will be priced at $3.00. The warrants will be exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance and have an exercise price of $3.75.

Immunomedics intends to use the proceeds from the offering primarily in continuing support of clinical and regulatory activities for IMMU-132, including submission of a NDA to FDA for accelerated approval in metastatic triple-negative breast cancer, and for working capital and general corporate purposes. (Original Source)

The public offering would dilute shareholders’ investments, and as such Immunomedics shares are currently dropping nearly 27% to $2.40 in Wednesday session. IMMU has a 1-year high of $5.44 and a 1-year low of $1.61. The stock’s 50-day moving average is $2.99 and its 200-day moving average is $3.04.

On the ratings front, Wells Fargo analyst Jim Birchenough downgraded IMMU to Hold, in a report issued on June 21. According to TipRanks.com, Birchenough has a yearly average return of 21.4%, a 53% success rate, and is ranked #77 out of 4193 analysts.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. 

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts